Updated 02:01 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,876.40 -0.25% CL 88.33 -0.26% BTC 64,613.34 +0.76%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,876 −0.25% BTC $64,613 +0.76% VIX 19.30 +3.21% latest tape · as of 02:01 UTC
The Screen · Healthcare · Medical Devices

BrainsWay Ltd.

BWAY · Nasdaq · USD · Market cap $463M · 129 employees

BrainsWay Ltd.

FAIL · Does not pass the screen
10.11 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price10.11 USD at the 13 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.00)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $15.07 to $17.33, base estimate $15.07 (screen dated 2026-11-13).

Current read
Distribution ?
Undervalued · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.00, read 2026-11-15
  • Ethical does not pass the values gate
Price10.11 USD
Fair value15.07
Ethical score70.0/100
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-10-02Read Markdown13.21-23.5% to today ✓Distribution gives way to Markdown after a 13% slide in 6 weeks
2026-08-24Read Distribution15.17-33.4% to today ✓Markdown gives way to Distribution with volume flow in agreement
2026-07-02Read Markdown14.63-30.9% to today ✓First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

BrainsWay Ltd. holds its Distribution at $10.11. The statistical read favours the buyers, held for 7 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateThe statistical read favours the buyers, held for 7 days
Price at the screen$10.11
Valuation50.04 trailing · 22.72 forward price to earnings
Values screenFAIL · score 70.0
Beta0.10
The Workings

Five Screens, Shown in Full

Does not pass. Interest/revenue 10.7%

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 1.07% Below 33% Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 10.62% Below 33% Cash held in interest-bearing accounts and securities is 10.6% of assets, under the one-third limit. Pass
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass
Revenue purity 10.72% Below 5% 10.7% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

BrainsWay does not pass the ethical screen. The binding factor is interest/revenue 10.7%.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

2026-10-25 Does not pass

BrainsWay does not pass the ethical screen. The binding factor is interest/revenue 10.7%.

2026-09-24 Clears

BrainsWay clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

Follow this verdict

Get an email when BWAY's ethical verdict changes

Today BWAY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 33% discount to our $15.07 fair value, moderate competitive moat, 35.40% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

15.07Conservative15.07Base case17.33Growth case 10.11Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 32.9% discount to the base estimate.

The Street's Range
18.80Street low 19.00Street average 20.00Street high 10.11Price

Third-party analyst targets. The average target sits +88% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $15.07, with a range of $15.07 to $17.33, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it stands out

A 35%-growth business trading at just 22.7x forward earnings, with a moderate competitive moat and minimal debt. That is a 33% discount to our $15.07 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.

The fundamentals · plain-English read
Forward P/E22.7xcheap for a company growing this fast
Trailing P/E50.0xexpensive: the price assumes strong growth ahead
EPS, trailing0.23
EPS, forward0.51
Revenue growth+35.4%strong top-line growth
Profit margin15.6%healthy profit margins
Return on equity12.8%a solid return on shareholder capital
FCF yield-1.33%
Debt to equity0.09minimal debt: a conservative balance sheet
Current ratio3.59comfortably covers its short-term bills
Beta0.10barely tracks the market's swings
Short interest, float0.01%
52-week range7.14 - 17.40
MoatMODERATE
Market cap$463M
Employees129

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

BWAY trades on Nasdaq (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-11 Markdown $10.67 -4.3% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-11-04 Markdown $11.15 -5.7% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-10-28 Markdown $11.82 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-10-21 Markdown $11.82 +0.4% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-10-14 Markdown $11.77 -10.9% Entry 7

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-10-02 Markdown · changed $13.21 -12.9% Entry 6

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-08-24 Distribution · changed $15.17 -3.6% Entry 5

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-07-24 Markdown $15.73 +7.5% Entry 4

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-07-18 Markdown $14.63 +0.0% Entry 3

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.

2026-07-03 Markdown $14.63 +0.0% Entry 2

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on BWAY

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in BWAY's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $16.73 -15.0% · $850 -15.0%
2 months $13.92 +2.2% · $1,022 +2.2%
3 months $13.74 +3.5% · $1,035 +3.5%
6 months $8.71 +63.3% · $1,633 +63.3%
1 year $5.73 +148.3% · $2,483 +148.3%
2 years $3.33 +327.2% · $4,272 +327.2%
3 years $1.10 +1,199.1% · $12,991 +1,199.1%
5 years $5.78 +145.9% · $2,459 +145.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BWAY does next, these words stay.

BrainsWay Ltd. · BWAY · Distribution · $10.11
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.